Oglemilast Inhibitor

Oglemilast suppresses pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast is an effective and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 0.5nM for PDE4D3). Oglemilast has the potential for inflammatory airway diseases.

Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking, Br J Pharmacol. 2008 Oct;155(3):288-90.
Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking, Br J Pharmacol. 2008 Oct;155(3):288-90.
Rabe KF, et al. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment,of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67.
Rabe KF, et al. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment,of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67.
Wunder F, et al. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter celllines. Mol Pharm. 2013 Oct 7;10(10):3697-705.
Wunder F, et al. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter celllines. Mol Pharm. 2013 Oct 7;10(10):3697-705.

Small volumes of Oglemilast, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5755299 is an inhibitor targeting Oglemilast.